Last updated: September 28, 2026
Ascorbyl palmitate is a niche, multifunctional excipient used primarily as a lipid-phase antioxidant, stabilizer, and vitamin C derivative. Its pharmaceutical market is small relative to mainstream excipients such as microcrystalline cellulose, magnesium stearate, tocopherols, and sodium metabisulfite. Demand is tied to soft-gel capsules, lipid-based formulations, nutraceuticals, cosmetics, and food preservation rather than to a large patented-drug franchise.
The financial outlook is stable but low-growth in conventional pharmaceuticals. Expansion is more likely in dietary supplements, functional foods, personal care, and oxidation-sensitive lipid formulations. Price performance depends on purity grade, manufacturing scale, regional regulation, and the cost of palmitic acid, ascorbic acid, energy, and specialty packaging.
What is ascorbyl palmitate and how is it used?
Ascorbyl palmitate is the fatty-acid ester of ascorbic acid and palmitic acid. It is also identified as vitamin C palmitate, L-ascorbic acid 6-palmitate, and CAS No. 137-66-6.
| Attribute |
Data |
| Chemical name |
L-Ascorbic acid 6-palmitate |
| CAS number |
137-66-6 |
| Molecular formula |
C22H38O7 |
| Molecular weight |
Approximately 414.54 g/mol |
| Functional class |
Antioxidant, stabilizer, lipid-phase protective agent |
| Physical profile |
White to pale yellow crystalline powder |
| Primary commercial grades |
Food, nutraceutical, cosmetic, pharmaceutical |
| Key formulation advantage |
Greater lipid compatibility than ascorbic acid |
The molecule is lipophilic and can protect oils, fats, phospholipids, and other oxidation-sensitive ingredients. In pharmaceutical formulations, it can reduce oxidative degradation in lipid-containing dosage forms, soft gels, emulsions, creams, and selected oral solid formulations.
Its use is generally functional rather than structural. It does not provide tablet binding, disintegration, viscosity control, or coating performance at the scale delivered by mainstream excipients.
How large is the pharmaceutical ascorbyl palmitate market?
The pharmaceutical segment is difficult to isolate because suppliers commonly report ascorbyl palmitate within broader antioxidant, vitamin derivative, nutraceutical, or specialty ingredient categories. Public company filings generally do not disclose revenue from this single compound.
The commercial market has four overlapping demand pools:
| Segment |
Relative demand |
Principal use |
| Food and beverage |
High |
Antioxidant in fats, oils, processed foods |
| Nutraceuticals |
High |
Vitamin C supplements, soft gels, lipid formulations |
| Cosmetics and personal care |
Medium to high |
Antioxidant and skin-care stabilization |
| Pharmaceuticals |
Low to medium |
Excipient and formulation stabilizer |
Pharmaceutical demand is therefore better measured through formulation activity and product registrations than through standalone market revenue. The addressable market is fragmented among ingredient distributors, contract manufacturers, supplement companies, and specialty chemical producers.
Growth is likely to track the following indicators:
- Expansion of soft-gel and lipid-based dosage forms.
- Growth in antioxidant-containing supplements.
- Greater use of oxidation-control systems in sensitive formulations.
- Demand for non-animal, traceable, and globally compliant excipients.
- Increased preference for multifunctional ingredients that combine nutritional and formulation value.
What is driving ascorbyl palmitate demand?
Lipid-based delivery systems
Ascorbyl palmitate is compatible with oils and lipid excipients where water-soluble ascorbic acid performs poorly. Demand benefits from soft-gel capsules, self-emulsifying drug delivery systems, lipid suspensions, and oil-based nutraceutical products.
Oxidation control
Oxidation can reduce potency, generate degradants, alter color, and affect odor. Formulators use ascorbyl palmitate alone or in combination with tocopherols, chelating agents, nitrogen control, oxygen-barrier packaging, and other antioxidants.
Its commercial value is highest when it lowers total formulation risk without requiring major changes to the dosage-form manufacturing process.
Nutraceutical growth
Nutraceuticals account for a meaningful share of commercial demand. Ascorbyl palmitate is marketed both as a vitamin C derivative and as a fat-compatible antioxidant. This dual positioning supports demand in products containing fish oils, botanical oils, carotenoids, essential fatty acids, and other oxidation-sensitive actives.
Clean-label and multifunctional formulation trends
Manufacturers may select ascorbyl palmitate when they want an ingredient recognized as a vitamin C derivative rather than a synthetic stabilizer with no nutritional identity. This advantage is stronger in consumer health and cosmetics than in prescription pharmaceuticals.
What factors constrain the market?
The market has several structural limitations.
First, ascorbyl palmitate is not indispensable. Formulators can substitute tocopherols, rosemary extracts, ascorbyl stearate, propyl gallate, butylated hydroxytoluene, butylated hydroxyanisole, or chelating-agent systems, depending on jurisdiction and product type.
Second, its antioxidant performance depends on formulation environment. It may not provide sufficient protection in aqueous systems and may require a complementary antioxidant package.
Third, the ingredient has a higher molecular weight than ascorbic acid and may deliver less vitamin C by weight. This limits its use where nutritional potency is the principal commercial objective.
Fourth, price-sensitive manufacturers can switch between qualified suppliers because the molecule is a commodity-like specialty ingredient rather than a proprietary excipient platform.
How does the ascorbyl palmitate supply chain affect financial performance?
Manufacturing typically involves esterification of ascorbic acid with palmitic acid, followed by purification, drying, milling, and packaging. Cost drivers include:
- Ascorbic acid input prices.
- Palmitic acid and fatty-acid feedstock costs.
- Solvent, catalyst, and purification requirements.
- Yield and batch rejection rates.
- Energy and drying costs.
- GMP controls for pharmaceutical-grade material.
- Residual-solvent and impurity testing.
- Freight, tariffs, and distributor margins.
Food and cosmetic grades can be produced with less extensive documentation than pharmaceutical-grade material. Pharmaceutical buyers may require supplier qualification, change-control commitments, certificates of analysis, microbial testing, elemental impurity controls, residual-solvent data, and stability information.
The supply chain is exposed to regional concentration. Production in Asia has helped contain costs, while customers in North America and Europe may pay premiums for dual sourcing, local inventory, audit access, and regulatory documentation.
What is the financial trajectory for ascorbyl palmitate suppliers?
The expected financial trajectory is steady rather than high-growth.
Near-term outlook
Revenue should remain supported by established food, supplement, and cosmetic applications. Pharmaceutical sales are likely to grow selectively as suppliers qualify the ingredient for additional formulations. Margin expansion depends more on grade mix and documentation than on volume.
Pharmaceutical-grade material can command a premium over food-grade material because of testing, traceability, quality systems, and lower tolerance for batch variability. The premium is vulnerable to buyer consolidation and supplier competition.
Medium-term outlook
Growth opportunities are strongest in:
- Lipid-based nutraceutical delivery.
- Oxidation-sensitive biologic or complex-molecule formulations.
- High-value topical and dermal products.
- Combination antioxidant systems.
- Contract development and manufacturing services.
- Regional supply agreements for regulated markets.
The main risk is substitution. If a formulation can use tocopherol or another antioxidant without changing performance, the buyer has limited incentive to accept a substantial price increase.
Long-term outlook
Long-term growth depends on whether ascorbyl palmitate gains broader acceptance as a pharmaceutical excipient rather than remaining primarily a food and cosmetic antioxidant. That transition requires more formulation data, stronger compendial support, and wider inclusion in excipient qualification databases.
What is the FDA regulatory status of ascorbyl palmitate?
Ascorbyl palmitate has established food-use recognition in the United States. FDA regulations identify ascorbyl palmitate as a substance permitted for direct food use under specified conditions, including 21 C.F.R. § 182.3149.
Pharmaceutical use is governed by the finished product’s regulatory submission and the excipient’s suitability for the proposed route, dose, and formulation. Food GRAS status does not automatically establish approval for every pharmaceutical application.
The FDA Inactive Ingredient Database is the relevant reference for prior use in approved drug products. Presence in the database can support excipient selection, but route, maximum daily exposure, dosage form, and concentration remain important. Sponsors may need additional justification when proposing a new route or materially higher exposure.
What is the European regulatory status?
In the European Union, ascorbyl palmitate is recognized as food additive E304(i). Pharmaceutical use depends on the applicable medicinal-product framework, national requirements, pharmacopoeial status, and the finished product dossier.
The European Pharmacopoeia and other recognized compendia can reduce qualification friction when a suitable monograph applies. Buyers still need to verify current monograph status, grade requirements, impurities, and supplier compliance.
Regulatory acceptance is strongest for oral, topical, food, and cosmetic applications. Parenteral use would require materially higher scrutiny because of sterility, endotoxin, particulate, extractables, and safety requirements.
What patents protect ascorbyl palmitate?
Ascorbyl palmitate itself is an old, well-known chemical entity and is not protected by a current basic composition-of-matter patent in ordinary commercial use. The commercial IP position generally relates to:
- Specific formulations.
- Combination antioxidant systems.
- Encapsulation or delivery technologies.
- Manufacturing and purification processes.
- Stability-enhancing packaging.
- Particular therapeutic or cosmetic uses.
A buyer should distinguish between freedom to operate for the ingredient and freedom to operate for a finished product. Purchasing nonproprietary ascorbyl palmitate does not eliminate risk from patents covering a delivery system or use combination.
Method-of-use and formulation patents
Potentially relevant claims may cover a composition containing ascorbyl palmitate with oils, phospholipids, tocopherols, carotenoids, botanical extracts, or active pharmaceutical ingredients. Patent risk is product-specific and cannot be inferred from the ingredient name alone.
Are there Paragraph IV challenges or patent litigation?
Ascorbyl palmitate is an excipient and vitamin derivative, not a conventional new drug with an Orange Book-listed reference product. Paragraph IV litigation is therefore generally not the central market-access issue.
The main legal risks arise in finished products, including:
- Patents covering a branded formulation.
- Patents covering a specific therapeutic use.
- Process patents held by suppliers.
- Trade-secret claims involving manufacturing conditions.
- Contract disputes involving specifications or supply exclusivity.
The ingredient itself is unlikely to create a conventional generic-entry bottleneck. The principal commercial barrier is formulation qualification, not patent expiry.
What is the Orange Book status of ascorbyl palmitate?
Ascorbyl palmitate does not have an Orange Book status as an independent active pharmaceutical ingredient. The Orange Book concerns approved drug products and their listed patents and exclusivity. An excipient may appear in an approved product without having independent Orange Book exclusivity.
For a finished drug, the relevant questions are the product’s active ingredient, approved labeling, listed patents, regulatory exclusivity, and formulation-specific intellectual property.
How strong is the ascorbyl palmitate patent estate?
The ingredient-level patent estate is weak because the compound is established and broadly available. The formulation-level estate can be moderate where a product uses a technically difficult lipid system, narrow particle-size profile, defined impurity limits, or a proprietary combination.
| IP category |
Relative strength |
| Basic molecule |
Low |
| General antioxidant use |
Low |
| Specific manufacturing process |
Low to medium |
| Controlled-purity pharmaceutical grade |
Medium |
| Proprietary delivery system |
Medium to high |
| Finished-drug formulation |
Product-specific |
| Supplier know-how |
Potentially meaningful but confidential |
How does ascorbyl palmitate compare with competing antioxidants?
| Ingredient |
Main advantage |
Main limitation |
| Ascorbyl palmitate |
Lipid compatibility and vitamin C identity |
Limited water-phase performance |
| Tocopherols |
Strong market adoption in oils |
Can be costly and formulation-dependent |
| Ascorbic acid |
High vitamin C content and water solubility |
Poor lipid compatibility and oxidation sensitivity |
| Ascorbyl stearate |
Lipophilic vitamin C derivative |
Less common commercial availability |
| Rosemary extract |
Consumer-friendly natural positioning |
Batch variability and odor/color concerns |
| BHA/BHT |
Low cost and established performance |
Consumer and regulatory restrictions in some markets |
| Propyl gallate |
Effective antioxidant in selected systems |
Application and regulatory limitations |
Ascorbyl palmitate competes on compatibility, label positioning, and formulation convenience rather than on lowest unit cost.
What generic entry risks exist?
Generic entry risk is limited at the excipient level because there is no exclusive branded drug franchise tied solely to ascorbyl palmitate. For finished products, launch risk depends on:
- Active-ingredient patent expiry.
- Orange Book-listed formulation or method-of-use patents.
- Regulatory exclusivity.
- Bioequivalence requirements.
- Demonstrated stability against oxidation.
- Access to qualified pharmaceutical-grade supply.
Manufacturing barriers are moderate. The chemistry is established, but pharmaceutical customers may impose strict impurity, particle-size, residual-solvent, and stability specifications. These requirements can slow supplier substitution without creating a durable legal monopoly.
Key Takeaways
- Ascorbyl palmitate is a niche pharmaceutical excipient with larger food, nutraceutical, and cosmetic markets.
- Its principal function is lipid-phase antioxidant protection.
- Revenue growth is likely to be steady and application-driven rather than rapid.
- Pharmaceutical-grade material earns a premium through documentation and qualification, not patent exclusivity.
- The compound has no meaningful current composition-of-matter exclusivity.
- Formulation and delivery-system patents may still affect finished products.
- Paragraph IV litigation and Orange Book exclusivity are generally not relevant to the ingredient itself.
- The strongest commercial opportunities are lipid-based supplements, soft gels, topical products, and oxidation-sensitive formulations.
- Supplier margins depend on grade, quality systems, regional inventory, and dual-sourcing value.
- Substitution by tocopherols, rosemary extract, ascorbic acid derivatives, and synthetic antioxidants limits pricing power.
FAQs
Is ascorbyl palmitate an active pharmaceutical ingredient?
No. It is generally used as an excipient, antioxidant, stabilizer, or vitamin derivative. Its regulatory role depends on the finished product and the jurisdiction.
Can ascorbyl palmitate be used in soft-gel capsules?
Yes. Its lipid compatibility makes it suitable for selected soft-gel and oil-based formulations, subject to product-specific stability and regulatory qualification.
Does ascorbyl palmitate have an expiration date?
The compound itself is not subject to a drug-patent expiration timeline in ordinary commercial use. Individual supplier specifications and product patents can have separate expiry dates.
Is pharmaceutical-grade ascorbyl palmitate interchangeable with food-grade material?
No. Interchangeability requires supplier qualification and confirmation of identity, purity, residual solvents, impurities, microbiological quality, particle size, and stability performance.
Which companies manufacture ascorbyl palmitate?
Supply is distributed across specialty chemical manufacturers, nutraceutical ingredient producers, and ingredient distributors, with sourcing concentrated in Asia and supplemented by regional distributors in North America and Europe.
References
-
European Commission. (n.d.). EU food additives database: E304(i), ascorbyl palmitate. European Commission.
-
U.S. Food and Drug Administration. (n.d.). 21 C.F.R. § 182.3149: Ascorbyl palmitate. Electronic Code of Federal Regulations.
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Ascorbyl palmitate. PubChem.
